
|Videos|October 17, 2014
Combining Targeted Agents for the Treatment of Lung Cancer
Author(s)Heather Wakelee, MD
Heather Wakelee, MD, associate professor, Stanford University School of Medicine, discusses the need to combine agents for the treatment of lung cancer.
Advertisement
Clinical Pearls
Heather Wakelee, MD, associate professor, Stanford University School of Medicine, discusses the need to combine agents for the treatment of lung cancer.
- It is widely believed that 1 molecularly-targeted agent will not be able to cure lung cancer.
- Long term responses have been observed with 1 targeted agent.
- Research needs to be conducted regarding which combinations of agents will be most beneficial or curative.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5


































